Transplant Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
発行: Mordor Intelligence LLP
ページ情報: 英文 111 Pages
Transplantation is among the preferred treatment option for many of the patients suffering from end-stage renal disease, and undergoing chronic dialysis therapy. There is a significant prevalence of patients suffering from end-stage renal disorders, for which the patients are being diagnosed at the later stage of the disease. In the past decade, the diagnostics have improved significantly with companies committed to developing better HLA typing technologies, antibody monitoring, instrument and software. Along with technological advancements, there are a growing number of transplant procedures being performed by the multispeciality hospitals in the developed markets and growing funding opportunities provided by the government and private collaborations. The diagnosis in transplants is done at both the donor and patients end to analyze the infection level inside the organ. However, some of the limitations include the high cost of transplants, insurance, and reimbursement policies, and social and ethical issues related to organ transplants.
The transplant diagnostics is necessary for the assessment of different aspects associated with a transplant during a pre-, peri-, and post-transplantation. The scope of the market report consists of segmentation by technology, product, transplant type, application, and geography.
Solid Organ Transplant Dominates the Market Segmentation by Transplant Type, Over the Forecast Period
Solid-organ transplantation, which started as an experimental approach in the 20th century is now considered as well-established and practical definitive treatment option for patients suffering from end-stage organ dysfunction. The major number of transplants done for kidney, followed by liver. Some of the technologies used during solid organ transplants include the emergence of molecular diagnostics. However, the greatest yield is obtained from PCR based techniques, which are widely accepted and used across the world. There is no gold standard for the transplant diagnostics, however, there are certain guidelines and tests recommended by the World Health Organization before and after the transplant procedures related to chronic advanced kidney diseases. The other transplants type is still in an experimental stage of development which is expected to grow at a healthy rate over the forecast period.
North America is Expected to Dominate the Market Among Other Regions, over the Forecast Period
Countries such as the United States and Canada are well-equipped with the funded organizations, infrastructure, as well as government participation in raising funds and awareness to promote transplantation of the diseased organs of the patients. There are several initiatives and awareness programs conducted by companies such as Roche collaborating with hospitals, organizations like the American Transplant Foundation to boost the organ donor rate. These companies are advanced in marketing new products for faster diagnostics of diseases before and after the transplants which are well accepted by the private organizations and government of the United States and Canada. Although there are more than 0.1 million awaiting transplants, mostly for kidney, there has been a steady rise in the number of liver donor rates followed by the deceased donor rate, which shows the improvement and demand of more diagnostics facilities across the healthcare facilities related to transplant. With a large section of the population across the world approach these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and dominance over the forecast period.
The technological advancement in terms of reagents effectiveness and affordability, clinicians decision making, as well as raising awareness and proper organ preservation facilities, are some of the present-day opportunities and challenges which the companies are expected to overcome, over the forecast period. Some of the major companies expanding in transplant diagnostics include Abbott Laboratories, Biomerieux SA, F Hoffmann La Roche, Qiagen, and ThermoFisher Scientific, among the rest.